202 492

Cited 6 times in

NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome

Authors
 Soo Rim Kim  ;  Yeo Jung Moon  ;  Sei Kwang Kim  ;  Sang Wook Bai 
Citation
 YONSEI MEDICAL JOURNAL, Vol.56(1) : 204-211, 2015 
Journal Title
YONSEI MEDICAL JOURNAL
ISSN
 0513-5796 
Issue Date
2015
MeSH
Adult ; Benzhydryl Compounds/pharmacology ; Benzhydryl Compounds/therapeutic use* ; Biomarkers/urine ; Case-Control Studies ; Creatinine/urine ; Female ; Heparin-binding EGF-like Growth Factor/urine* ; Humans ; Male ; Middle Aged ; Nerve Growth Factor/urine* ; Surveys and Questionnaires ; Treatment Outcome ; Urinary Bladder, Overactive/drug therapy* ; Urinary Bladder, Overactive/physiopathology ; Urinary Bladder, Overactive/urine* ; Urodynamics
Keywords
Heparin-binding EGF-like growth factor ; nerve growth factor ; overactive bladder ; questionnaire ; urinary biomarkers
Abstract
PURPOSE: To determine whether levels of nerve growth factor (NGF) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) can be used to objectively assess overactive bladder syndrome (OAB) treatment outcome and to evaluate the effects of fixed-dose fesoterodine on OAB symptoms.
MATERIALS AND METHODS: This study included 124 participants (62 patients with OAB and 62 controls) in Severance Hospital between 2010 and 2012. In patients with OAB, 4 mg fesoterodine was administered once daily. Repeated evaluations of putative biomarker levels, urine creatinine (Cr) levels, and questionnaire responses, including the Overactive Bladder Symptom Score (OABSS) and the Overactive Bladder Questionnaire (OAB q), were performed from baseline to 16 weeks.
RESULTS: Urinary levels of NGF/Cr (OAB: 1.13±0.9 pg/mg; control: 0.5±0.29 pg/mg) and HB-EGF/Cr (OAB: 8.73±6.55 pg/mg; control: 4.45±2.93 pg/mg) were significantly higher in subjects with OAB than in controls (p<0.001). After 16 weeks of fixed-dose fesoterodine treatment, urinary NGF/Cr levels (baseline: 1.13±0.08 pg/mg; 16 weeks: 0.60±0.4 pg/mg; p=0.02) and HB-EGF/Cr levels significantly decreased (baseline: 8.73±6.55 pg/mg; 16 weeks: 4.72±2.69 pg/mg; p=0.03, respectively). Both the OABSS and OAB q scores improved (p<0.001). However, there were no a statistically significant correlations between these urinary markers and symptomatic scores.
CONCLUSION: Urinary levels of NGF and HB-EGF may be potential biomarkers for evaluating outcome of OAB treatment. Fixed-dose fesoterodine improved OAB symptoms. Future studies are needed to further examine the significance of urinary NGF and HB-EGF levels as therapeutic markers for OAB.
Files in This Item:
T201500066.pdf Download
DOI
10.3349/ymj.2015.56.1.204
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Sei Kwang(김세광)
Moon, Yeo Jung(문여정)
Bai, Sang Wook(배상욱) ORCID logo https://orcid.org/0000-0001-7724-7552
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/139203
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links